 |
Previous Article | Next Article 
Volume 16, Number 19,
Issue of October 1, 1996
pp. 6255-6264
Copyright ©1996 Society for Neuroscience
GAT-3, a High-Affinity GABA Plasma Membrane Transporter, Is
Localized to Astrocytic Processes, and It Is Not Confined to the
Vicinity of GABAergic Synapses in the Cerebral Cortex
Andrea Minelli1,
Silvia DeBiasi2,
Nicholas C. Brecha3, 4, 5, 6, 7,
Laura Vitellaro
Zuccarello2, and
Fiorenzo Conti1
1 Institute of Human Physiology, University of Ancona,
I-60131 Ancona, Italy; 2 Department of General Physiology
and Biochemistry, Section of Histology and Human Anatomy, University of
Milan, 20133 Milan, Italy; 3 Department of Neurobiology,
4 Department of Medicine, 5 Brain Research
Institute, and 6 CURE: Digestive Diseases Research Center,
UCLA School of Medicine; and 7 Veterans Administration
Medical Center, Los Angeles, California 90073
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES
ABSTRACT
The termination of GABA synaptic action by high-affinity,
Na+-dependent, neuronal, and glial plasma membrane
transporters plays an important role in regulating neuronal activity in
physiological and pathological conditions. We have investigated the
cellular localization and distribution in the cerebral cortex of adult
rats of one GABA transporter (GAT), GAT-3, by immunocytochemistry with
affinity-purified polyclonal antibodies directed to its predicted C
terminus that react monospecifically with a protein of ~70 kDa.
Light microscopic studies revealed specific GAT-3 immunoreactivity (ir)
in small punctate structures, and it was never observed in fibers or
cell bodies. No changes in immunostaining were observed in sections
incubated with GAT-3 antibodies preadsorbed with the related rat GAT-1
or mouse GAT-2/BGT-1 C-terminal peptides, whereas in sections incubated
with GAT-3 antibodies preadsorbed with rat GAT-3 C-terminal peptide, ir
was not present. The highest number of GAT-3-positive puncta was in
layer IV and in a narrow band corresponding to layer Vb, followed by
layers II and III. Many GAT-3-positive puncta were in close association
with pyramidal and nonpyramidal neuron cell bodies. Ultrastructural
studies showed that GAT-3 ir was localized exclusively to astrocytic
processes, which were found in the neuropil and adjacent to axon
terminals having either symmetric or asymmetric specializations. In
sections processed by both preembedding labeling for GAT-3 and
postembedding immunogold labeling for GABA, only some of the
GAT-3-positive astrocytic processes were found close to GABAergic
profiles.
These findings on the localization of GAT-3 in the cerebral cortex
indicate that this transporter mediates GABA uptake into glial cells,
and suggest that glial GABA uptake may function to limit the spread of
GABA from the synapse, as well as to regulate overall GABA levels in
the neuropil.
Key words:
synaptic transmission;
GABA;
GABA transporters;
neocortex;
symmetric and asymmetric synapses;
astrocytes
INTRODUCTION
The magnitude and duration of GABA synaptic action
are regulated by plasma membrane proteins, termed GABA transporters
(GATs), which mediate a high-affinity,
Na+/Cl -dependent, uptake of GABA into
presynaptic axon terminals and glial processes (Iversen and Neal, 1968 ;
Iversen and Snyder, 1968 ; Neal and Iversen, 1969 ; Iversen, 1971 ;
Iversen and Kelly, 1975 ). GATs may also release GABA into the
extracellular space in a Ca2+-independent, nonvesicular
manner (Schwartz, 1982 ; Pin and Bockaert, 1989 ; Attwell et al., 1993 ;
Levi and Raitieri, 1993 ), and they are targets for pharmacological
intervention in neurological diseases characterized by GABAergic
imbalance, such as epilepsy (Schousboe et al., 1983 ; Krogsgaard-Larsen
et al., 1987 ; During et al., 1995 ). To date, four cDNAs encoding highly
homologous GATs have been isolated from the rodent and human nervous
systems (Guastella et al., 1990 ; Borden et al., 1992 , 1994b ; Clark et
al., 1992 ; Liu et al., 1993 ). GATs have different pharmacological
properties (Guastella et al., 1990 ; Borden et al., 1992 , 1994b ; Clark
et al., 1992 ; Yamauchi et al., 1992 ; Liu et al., 1993 ) and tissue
distributions (Ikegaki et al., 1994 ; Brecha et al., 1995 ; Durkin et
al., 1995 ; Minelli et al., 1995 ; Ribak et al., 1996 ).
In a previous study, we reported that numerous neurons and some
astrocytes express GAT-1 mRNA, and that GAT-1 immunoreactivity (ir) is
localized to axon terminals forming symmetric synapses as well as to
astrocytic processes (Minelli et al., 1995 ). This indicates that GAT-1,
which exhibits a pharmacological profile (Guastella et al., 1990 )
typical of a ``neuronal'' transporter (Beart et al., 1972 ; Iversen
and Kelly, 1975 ; Bowery et al., 1976 ; Larsson et al., 1983 ; Mabjeesh et
al., 1992 ), also mediates GABA uptake into glial cells. These findings
suggest that the organization of GABA uptake systems in the cerebral
cortex is more complex than previously believed on the basis of
pharmacological studies, and emphasize the importance of defining
further the cellular localization of GATs.
Immunoblot, immunocytochemical, and in situ hybridization
studies published to date indicate that GAT-3, a predicted
627-amino-acid protein found only in the nervous system (Borden et al.,
1992 ; Ikegaki et al., 1994 ), is either absent or very weakly expressed
in the cerebral cortex (Clark et al., 1992 ; Ikegaki et al., 1994 ;
Brecha et al., 1995 ; Durkin et al., 1995 ). Because GAT-2 is not present
in the cortex and it is expressed only by arachnoid and ependymal cells
(Ikegaki et al., 1994 ; Durkin et al., 1995 ), these findings imply that
glial GABA transport in the cerebral cortex is mediated mainly by
GAT-1. However, it seems unlikely that GAT-1 is the sole transporter to
mediate glial GABA uptake in the neocortex, because there is
significant glial GABA uptake and there is a limited expression of
GAT-1 in astrocytes (Minelli et al., 1995 ). To better understand GABA
uptake systems in the cerebral cortex, we have used a new and specific
affinity-purified antibody to evaluate the cellular localization and
distribution of GAT-3 in the cerebral cortex of adult rats.
MATERIALS AND METHODS
Adult albino rats (Harlan Sprague Dawley, San Diego, CA, and
Charles River, Milan, Italy), weighing 180-250 gm, were used in the
present studies. Care and handling of animals were approved by the
Animal Research Committees of the VAMC-West Los Angeles and of the
University of Ancona.
Tissue preparation
For light microscopy, rats were deeply anesthetized with 30%
chloral hydrate and perfused transcardially with 0.1 M PBS,
pH 7.4, followed by 4% paraformaldehyde (PFA) in 0.1 M
phosphate buffer (PB; pH 7.4). For electron microscopy, rats were
perfused with 4% PFA plus 1% glutaraldehyde in PB. Brains were
post-fixed for 1-2 hr at 4°C in the same fixative used for the
perfusion, cut with a vibratome in either coronal or parasagittal plane
into 25- to 30-µm-thick sections, which were collected serially in
PBS and stored at 4°C until processing. Data were collected from a
region of the parietal cortex characterized by the presence of a
conspicuous layer IV, with intermingled dysgranular regions, densely
packed layers II and III, and a relatively cell-free layer Va. This
region corresponds to the first somatic sensory cortex (SI), as defined
by Zilles (1985) and Chapin and Lin (1990) .
Immunocytochemistry
Antibody production. Affinity-purified rabbit
polyclonal antibodies (369-D and 374-E) directed to the predicted C
terminus (Borden et al., 1992 ; Clark et al., 1992 ) of rat GAT-3
(rGAT-3607-627) were used for these studies. Rabbits were
initially immunized with 100 nmol of the GAT-3607-627
conjugated to keyhole limpet hemocyanin (KLH) in complete Freund's
adjuvant, and subsequently immunized at 4-6 week intervals with 50 nmol of the GAT-3607-627 conjugated to KLH in incomplete
Freund's adjuvant. Plasma was harvested at regular intervals after
each immunization, and sera were tested for specific immunostaining.
Selected sera were affinity-purified using an Epoxy-Sepharose column
prepared with the C-terminal sequence of GAT-3 following the
manufacturer's instructions (Pharmica Biotech, Piscataway, NJ).
Antibodies were eluted with 3 M KSCN, collected and
concentrated with a Centriprep-30 (Amicon, Beverly, MA), and stored in
1% BSA and 0.1 M NaN3 in 0.1 M PB
at 70°C.
Antibody characterization by immunoblotting and
immunoblocking. Sprague Dawley rats (150-250 gm) were perfused
with cold 4 mM Tris-HCl, pH 7.4, containing 0.32 M sucrose, 1 mM EDTA, 0.5 mM
phenylmethylsulphonyl fluoride (PMSF), and 0.5 mM
N-ethylmaleimide (NEM). After the meninges were removed,
brains were homogenized by glass-Teflon homogenizer in 10 vol of
ice-cold buffer (0.32 M sucrose; 4 mM Tris-HCl,
pH 7.4; 1 mM EDTA; and 0.25 mM dithiothreitol)
(Ikegaki et al., 1994 ). The homogenate was centrifuged at 1000 × g for 15 min at 4°C. The pellet was discarded, and
aliquots of the supernatant (total brain extract) were either used
immediately or stored at 80°C. A crude membrane preparation of the
cerebral cortex was also made by the same procedure. After removing the
low-speed pellet, the remaining supernatant was recentrifuged at
105,000 × g for 1 hr at 4°C and the resulting crude
membrane pellet (Thomas and McNamee, 1990 ) was resuspended in
homogenization buffer containing protease inhibitors (1 mM
EDTA, 0.5 mM PMSF, 0.5 mM NEM) and either used
immediately or stored at 80°C. Protein concentrations were measured
according to Bradford (1976) , with the Bio-Rad protein assay kit
(Bio-Rad Laboratories, Hercules, CA). Aliquots of total brain extract
and of crude membrane fraction were mixed with equal volumes of 2×
electrophoresis sample buffer with or without 4 M urea
(final concentration). The samples were subjected to 10% SDS-PAGE with
a 3% stacking gel under reducing conditions, and the separated
proteins were electrophoretically transferred to a nitrocellulose
filter (0.45 µm) according to the method of Towbin et al. (1979) .
After the transfer, the gels were stained with Coomassie blue and
visually examined for transfer efficiency. The blots were sequentially
incubated with the GAT-3 antibody (369D, dilution 1:500) and goat
anti-rabbit IgG conjugated to horseradish peroxidase and then reacted
with BM chemoluminescence Western blotting kit (Boeh- ringer
Mannheim, Mannheim, Germany) following the instructions provided by the
manufacturer. Labeled bands were visualized on X-Omat AR films (Eastman
Kodak, Rochester, NY). As a control, blots were submitted to the same
immunolabeling procedure except that the primary antibody was either
omitted or preadsorbed with 10 5 M rat
GAT-3607-627 peptide.
GAT-3 antibodies were characterized also by immunoblocking with
10 5 M or 10 6 M rat
GAT-3607-627 peptide, with 10 5 M
rat GAT-1588-599, or mouse GAT-2/BGT-1596-614,
C-terminal peptides (Guastella et al., 1990 , 1992 ; Borden et al., 1992 ;
Yamauchi et al., 1992 ; Liu et al., 1993 ). In all blocking experiments,
the antibody dilution was 1:1000.
To directly compare GAT-3 and GAT-1 immunostaining, sections adjacent
to those processed with GAT-3 antisera were incubated with
affinity-purified polyclonal antibodies (341-F and 346-J) (Minelli et
al., 1995 ) directed to the predicted C terminus of rat GAT-1
(rGAT-1588-599) (Guastella et al., 1990 ) peptide.
Procedure. Free-floating sections were preincubated for 1 hr
in normal goat serum (NGS; 10% in PBS) with 0.5% Triton X-100 and
then incubated overnight at 4°C in GAT-3 or GAT-1 primary antibodies
(dilution 1:1000 for both antibodies). The next day, sections were
rinsed in PBS and incubated for 15 min in 10% NGS and then in
biotinylated anti-rabbit IgG at a dilution of 1:100 in PBS (1 hr at
room temperature or overnight at 4°C). Sections were rinsed in PBS,
incubated in avidin-biotin-peroxidase complex (ABC) (Hsu et al.,
1981 ) for 30 min, washed several times in PBS, and then incubated first
in 50-75 mg DAB/100 ml Tris (0.05 M) and then in fresh DAB
with 0.02% H2O2. Sections were washed in PBS,
mounted on subbed slides, air-dried, dehydrated, and coverslipped.
For electron microscopy, vibratome sections were pretreated to increase
the penetration of immunoreagents by a mild ethanol treatment (10, 25, and 10%; 5 min each). GAT-3 antibodies were used at 1:1000 dilution;
Triton X-100 was not used. After completion of the ICC procedure,
sections were washed in PB, post-fixed for ~30 min in 2.5%
glutaraldehyde in PB, washed in PB, and post-fixed for 1 hr in 1%
OsO4. After dehydration, sections were cleared in propylene
oxide, flat-embedded in Epon-Spurr between acetate foils (Aclar; Ted
Pella, Redding, CA), and polymerized at 60°C for 36 hr. When
polymerization was complete, the embedded sections were examined under
a dissecting microscope. Small strips of cortex were excised with razor
blades and either glued to cured resin blocks or reembedded in
Epon-Spurr. Semithin (1 µm) sections were cut with a Reichert
ultramicrotome and collected on glass slides without counterstaining
for light microscopical inspection. Ultrathin sections were cut either
from the surface or from the edge (i.e., perpendicular to the plane of
section), counterstained with uranyl acetate and lead citrate or with
lead citrate only, and examined with a Jeol T8 electron microscope.
Some ultrathin sections from different animals were processed first for
the visualization of GAT-3 ir and subsequently for the demonstration of
GABA ir by a standard postembedding immunogold method (De Biasi et al.,
1994 ) using a rabbit polyclonal GABA antiserum (Sigma, St. Louis, MO).
Briefly, thin sections collected on nickel grids were immersed in 1%
sodium borohydride (15 min) and, after several rinses in Tris-buffered
saline (TBS), incubated at room temperature with 10% NGS (30 min) and
with the primary antiserum (1:10,000, overnight). After extensive
rinses, grids were incubated in a solution of goat anti-rabbit IgG
coupled to 15 nm gold particles (Biocell, Cardiff, UK) diluted 1:30 (1 hr) and then counterstained with uranyl acetate and lead citrate or
with lead citrate only. Specificity of the immunogold labeling was
evaluated by blocking experiments in which the anti-GABA serum was
adsorbed with GABA, in both free and conjugated forms. Method
specificity was controlled by the application of rabbit nonimmune serum
as well as by processing series of sections omitting various stages of
the regular staining sequence. Preadsorption of the antiserum, diluted
for tissue reaction, with GABA (free or conjugated) abolished labeling,
as did substitution of the primary antiserum with preimmune serum. The
pattern of GABA immunogold labeling obtained was the same as that
described previously (Beaulieu et al., 1994 ). Terminals with asymmetric
specialization were always devoid of labeling. Nonspecific or
background labeling was low in our preparations and, therefore, it was
not necessary to perform a statistical analysis of the distribution of
gold particles to determine whether a profile was labeled.
The immunogold protocol used to visualize GABA ir allowed the
preservation of the DAB reaction product indicating GAT-3 ir.
Therefore, in all of the thin sections examined, the following profiles
could be identified: (1) profiles containing only the granular
electron-dense reaction product of DAB indicating the presence of GAT-3
ir; (2) profiles containing only gold particles indicating the presence
of GABA; and (3) profiles unlabeled by either antibodies.
RESULTS
The specificity of the antibody was examined by immunoblot. The
purified antibody against GAT-3 revealed a band of ~70 kDa both in
total brain extract and in the crude membrane fraction of the cerebral
cortex (Fig. 1A,B).
Omission of the primary antibody or preadsorption with
GAT-3607-627 peptide prevented labeling of the blots (Fig.
1C).
Fig. 1.
Specificity of the GAT-3 antibody assessed by
immunoblotting. 100 µg of protein was loaded for each lane.
A, Total brain extract solubilized in sample buffer
without urea; a fraction of incompletely solubilized antigen remains at
the gel top. B, Crude membrane fraction of the cerebral
cortex solubilized in sample buffer containing 4 M urea.
C, Crude membrane fraction processed with GAT-3 antibody
preadsorbed with 10 5 M
GAT-3607-627 peptide. Open arrow indicates
the gel top.
[View Larger Version of this Image (55K GIF file)]
GAT-3 ir was differentially distributed in the brain: high levels were
in the olfactory bulb, thalamus, hypothalamus, and brainstem, whereas
low levels were in the caudate-putamen, cerebral cortex, hippocampus,
and cerebellum (Fig. 2). In the cerebral cortex, GAT-3
ir was localized exclusively to small punctate structures that were
difficult to resolve at the light microscopic level and never appeared
as labeled fibers or cell bodies (Figs. 3, 4, 5, 6). Specific
GAT-3 ir was prevented when GAT-3 antibodies had been preadsorbed with
10 5 or 10 6 M rat
GAT-3607-627 (Fig. 4D),
whereas no changes were observed in sections incubated with GAT-3
antibodies preadsorbed with 10 5 M rat
GAT-1588-599 and mouse GAT-2/BGT-1596-614
C-terminal peptides (Fig. 4B,C). The same
pattern of GAT-3 ir was observed in sections from different animals,
and it did not show any significant regional variations along the
rostro-caudal or medio-lateral extent of the neocortex.
Fig. 2.
Parasagittal section of the rat brain
illustrating the regional distribution of GAT-3 ir. Cb,
Cerebellum; CP, caudate-putamen; HF, hippocampal
formation; Hy, hypothalamus; T, thalamus. Scale
bar, 2 mm.
[View Larger Version of this Image (110K GIF file)]
Fig. 3.
Distribution of GAT-3 ir in SI of adult rats
perfused with 4% paraformaldehyde only (A) or with 4%
paraformaldehyde and 1% glutaraldehyde (B).
C, A Nissl-stained section adjacent to A
and B. Roman numerals indicate cortical
layers. D, Distribution of GAT-1 in SI of an adjacent
section. Scale bar, 150 µm.
[View Larger Version of this Image (147K GIF file)]
Fig. 4.
A, GAT-3 ir in SI is localized
exclusively to small punctate structures that are densely packed around
cell bodies, and is highest in layer IV and Vb. B-D,
Adjacent sections processed with GAT-3 antibody preincubated with
10 5 M rat GAT-1588-599
(B), mouse GAT-2/BGT-1593-602
(C), and 10 5 M rat
GAT-3607-627 (D). GAT-3 ir does not change
in B and C, but it is completely
abolished in D. Scale bar, 100 µm.
[View Larger Version of this Image (166K GIF file)]
Fig. 5.
GAT-3 ir within puncta outline large cell
bodies that are likely to be pyramidal cells (arrows in
A and B) and small cells that are likely
to be nonpyramidal neurons (arrowheads in
A and C). Scale bar, 15 µm.
[View Larger Version of this Image (137K GIF file)]
Fig. 6.
GAT-3 (A) and GAT-1
(B) ir in semithin sections. With both antisera,
labeling is in punctate structures scattered throughout the neuropil
among unlabeled cell bodies. GAT-3-immunoreactive puncta are small and
evenly distributed (A), whereas some of the
GAT-1-immunoreactive puncta are large (arrows) and
surround neuronal cell bodies and major dendrites (B).
The apparent GAT-3 labeling of perivascular structures has not been
confirmed at the electron microscopic level. Phase-contrast microscopy;
noncounterstained sections. Layer V. Scale bar, 25 µm.
[View Larger Version of this Image (109K GIF file)]
GAT-3 ir was present throughout the depth of SI, but the apparent
density of positive puncta varied in the different layers. The highest
level of GAT-3 ir was observed in layer IV and in a narrow band
corresponding to the lower portion of layer V (Vb; Figs.
3A,B, 4A). In these layers, the
neuropil was filled by numerous, heavily stained, GAT-3-positive
puncta, which were densely packed around unstained cell body profiles
(Figs. 3A, 4A). In layers II and III,
GAT-3 ir exhibited the same features but was less intense. Ir was faint
in layers I, Va, and VI, where positive puncta were sparser and less
intensely stained than in the other layers (Figs. 3A,
4A). Comparison between GAT-1 and GAT-3 ir showed
that GAT-3 ir, although less intense, displayed a laminar pattern
similar to that of GAT-1 ir (Fig. 3C).
GAT-3 ir was not evenly distributed in SI: in all cortical layers, but
particularly in layers VI and IV, restricted areas of tissue were
observed, in which the expression of GAT-3 was very low (Figs.
3A, 4A). Patchy regions exhibited
clear-cut borders (Figs. 3A, 4A) and were
observed in all sections from all animals.
GAT-3-positive puncta were small in size (<1 µm in diameter) and
were observed both in the neuropil and in close relationship with cell
bodies. In the latter case, GAT-3-positive puncta formed a continuous
sheet around the somata of both pyramidal and nonpyramidal neurons
(Fig. 6A-C). In layers II, III, and V,
GAT-3-positive puncta were also in close association with the proximal
portion of basal (Fig. 5A) and apical (Fig.
5B) dendrites of pyramidal cells. GAT-3-positive puncta were
different from GAT-1-positive puncta since (1) they were more numerous
in the neuropil, and (2) they were smaller than the majority of
GAT-1-immunoreactive puncta. However, the distribution of
GAT-3-positive puncta around somata and dendrites of cortical neurons
(Fig. 5) is similar to that of GAT-1 (Fig. 6) (see also
Fig. 8 in Minelli et al., 1995 ).
Fig. 8.
Simultaneous subcellular localization of GAT-3 and
GABA ir. A, A GAT-3-labeled astrocytic process
(asterisk) is adjacent to a GABA-containing axon
terminal (T) forming a symmetric synapse
(arrow) on an unlabeled dendrite. B, A
GAT-3-labeled astrocytic process (asterisk) is adjacent
to a GABA-immunogold-labeled dendrite (D) that receives
a symmetric synapse (arrow) from a
GABA-immunogold-labeled terminal (T) and an
asymmetric synapse from an unlabeled axon terminal
(U). C, A GAT-3-labeled astrocytic
process (asterisk) is adjacent to an unlabeled axon
terminal (U) with asymmetric specialization. A
GABA-immunogold-labeled terminal (T) makes a
symmetric synapse (arrow) on a dendrite. Uranyl acetate
and lead citrate counterstaining. Scale bar, 0.5 µm.
[View Larger Version of this Image (95K GIF file)]
The ultrastructural pattern of GAT-3 labeling was the same in all
layers of the cortex. GAT-3 ir was found exclusively in distal
astrocytic processes, characterized by an irregular contour, whereas
astrocytic cell bodies and neuronal profiles were always unlabeled
(Fig. 7). Electron-dense reaction product was present
along the cytoplasmic side of the plasma membrane and in cytoplasmatic
granular patches. Labeled astrocytic processes were evenly distributed
throughout the neuropil, as they were found adjacent to axon terminals
making either symmetric (Fig. 7A,B) or asymmetric
(Fig. 7C,D) synaptic contact with cell bodies
(Fig. 7A), dendrites (Fig. 7B), dendritic spines
(Fig. 7C,D), or close to neuronal profiles that
did not form synaptic contacts in the plane of section (not shown).
Analysis of patchy regions devoid of GAT-3 ir showed that cortical
tissue was normally preserved, but lacked GAT-3 ir.
Fig. 7.
Subcellular localization of GAT-3 ir.
A, A GAT-3-labeled astrocytic process
(asterisk) is adjacent to an axon terminal
(T) making a symmetric synapse
(arrow) on a neuronal cell body. N,
Nucleus; G, Golgi complex. B, A
GAT-3-labeled astrocytic process (asterisk) is adjacent
to an axon terminal (T) making a symmetric
synapse (arrow) on a dendrite. C,
D, GAT-3-labeled astrocytic processes
(asterisks) are adjacent to axon terminals
(T) making asymmetric synapses
(arrows) on dendritic spines. Lead citrate
counterstaining. Scale bar, 0.5 µm.
[View Larger Version of this Image (152K GIF file)]
In sections reacted for postembedding immunogold visualization of GABA,
some of the GAT-3-stained astrocytic processes were found adjacent
either to terminals with symmetric specialization (Fig.
8A) or to dendrites (Fig.
8B) that were selectively enriched in gold particles
coding for GABA. However, most of the GAT-3-stained astrocytic
processes were not associated with GABA-positive processes: of these,
some were close to terminals forming asymmetric synapses (Fig.
8C). None of these astrocytic processes contained GABA ir
(Fig. 8A-C).
DISCUSSION
The present study shows that in the cerebral cortex of adult rats
GAT-3 is localized exclusively to astrocytic processes, and that the
distribution of GAT-3 ir processes is compatible with a role of GAT-3
in the regulation of GABA levels in the extracellular space.
Antibody specificity and comparison with previous studies
To visualize the distribution of GAT-3, affinity-purified
polyclonal antibodies were raised against a synthetic peptide
corresponding to the predicted C terminus of rat GAT-3. The
characterization of these antibodies by immunoblot analysis of rat
brain homogenates and crude membrane fractions of cerebral cortex
showed that they monospecifically react with a protein of ~70 kDa,
consistent with the molecular mass predicted by the analysis of cloned
cDNA (Borden et al., 1992 ; Clark et al., 1992 ). The specificity of
these antibodies was demonstrated further by immunoblocking studies,
which revealed that GAT-3 ir was prevented when GAT-3 antibodies were
preadsorbed with their specific cognate peptide, but not with other
related GABA transporter C-terminal peptides.
Overall, the distribution of GAT-3 ir described here is in agreement
with previous immunocytochemical (Ikegaki et al., 1994 ) and in
situ hybridization (Clark et al., 1992 ; Durkin et al., 1995 )
studies, which also showed that the highest levels of GAT-3 expression
are in olfactory bulb, hypothalamus, thalamus, and brainstem. A major
difference between earlier descriptions and the present study concerns
only the level of GAT-3 expression in the cerebral cortex. These
studies indicate that GAT-3 is either absent or very weakly expressed
in the cerebral cortex (Clark et al., 1992 ; Ikegaki et al., 1994 ;
Brecha et al., 1995 ; Durkin et al., 1995 ), whereas our results show
that neocortex exhibits low, but not negligible, levels of GAT-3. Given
the specificity of the antibodies used in the present study, it is
likely that the level of GAT-3 mRNA or protein was underestimated in
earlier studies, perhaps because of the very high levels of GAT-3
expression elsewhere in the brain.
In the cerebral cortex, GAT-3 is expressed only by astrocytes
GAT-3 ir is localized in numerous, small punctate structures
throughout the cerebral cortex. Ultrastructural studies revealed that
neuronal cell bodies, dendrites, and axon terminals were always
unlabeled, and they showed that GAT-3 ir was exclusively localized to
many small processes. Their irregular contours conformed to outlines of
surrounding neuropilar elements, and previous studies have shown that
these features are typical of astrocytic processes (Peters et al.,
1991 ). Thus, although we cannot rule out the possibility that some
cortical neurons synthesize GAT-3 at such low levels that they cannot
be visualized by current immunocytochemical procedure, the present
study indicates that in the cerebral cortex GAT-3 is expressed
exclusively in astrocytes and it is localized to their processes.
The existence of GABA uptake systems associated with glial cells was
demonstrated in the cerebral cortex in early autoradiographic studies,
which showed a significant [3H] -alanine uptake in
cortical slices and synaptosome preparations (Schon and Kelly, 1975 ),
and in pharmacological studies showing that GABA transport in cortical
astrocytic membranes is highly sensitive to -alanine (Mabjeesh et
al., 1992 ).
The present anatomical results on the cellular localization of GAT-3
are in agreement with previous data. For instance, heterologous cells
transfected with GAT-3 and ``glial'' GABA transport have similar
pharmacological properties (Borden et al., 1992 ; Clark et al., 1992 ;
Clark and Amara, 1994 ). That is, GABA uptake by GAT-3 is strongly
inhibited by -alanine and -proline (Borden et al., 1992 ; Clark et
al., 1992 ; Clark and Amara, 1994 ), and it is not inhibited by the
``neuronal'' GABA transport inhibitors ACHC and DABA (Iversen and
Kelly, 1975 ; Neal and Bowery, 1977 ; Gavrilovic et al., 1984 ; Kanner and
Bendahan, 1990 ; Mabjeesh et al., 1992 ). Furthermore, GAT-3 is expressed
by rat retinal Muller cells (Brecha et al., 1995 ), by hippocampal
astrocytic processes (Ribak et al., 1996 ), and by cultured astrocytes
(Borden et al., 1994a ). The reported expression of GAT-3 in neurons
located in the brainstem and in a few amacrine cells of the retina
(Clark et al., 1992 ; Brecha et al., 1995 ) does not contradict the
present findings: rather, it suggests that there is a regional
heterogeneity in GAT-3 cellular expression. Whether other
neurotransmitter transporters display a similar regional
heterogeneity in their cellular expression pattern remains an
interesting challenge for future investigations.
The demonstration that cortical astrocytes express GAT-3 together with
previous findings on astrocytic expression of GAT-1 (Minelli et al.,
1995 ) raises some interesting questions. First, are GAT-1 and GAT-3
coexpressed? Although GAT-3 is expressed more robustly than GAT-1 in
astrocytes, astrocytes expressing GAT-1 and GAT-3 display the same
laminar segregation and, at least in part, an overlapping distribution;
it is possible, therefore, that a subpopulation of cortical astrocytes
may coexpress both GAT-1 and GAT-3. Second, what is the relative
contribution of each of these transporters to overall GABA uptake by
glial cells in the cerebral cortex? There are no experimental studies
addressing this question. However, because GAT-1 and GAT-3 transport
exhibit different ionic dependences and inhibitor sensitivities in
heterologous cell systems (Guastella et al., 1990 ; Borden et al., 1992 ;
Clark et al., 1992 ; Keynan et al., 1992 ), it is conceivable that the
relative contribution of GAT-1 and GAT-3 to glial GABA uptake is
determined by different regulatory mechanisms, e.g., different
responses to the composition of the extracellular milieu
and/or different regulation of GAT's activity and/or expression. For
instance, protein kinase C (PKC) activators, which increase GABA uptake
in cells transfected with GAT-1 (Corey et al., 1994 ), reduce glial GABA
transport in primary astrocyte cultures (Gomeza et al., 1991 ). A
differential regulation of astrocytic GAT-1 and GAT-3 would allow a
great adaptability in the fine regulation of GABA extracellular levels
under various physiological conditions.
The distribution of GAT-3 in the cerebral cortex is compatible with
a dual physiological role
The major features of the distribution of GAT-3 ir in the cerebral
cortex, as revealed for the first time by this study, are as follows:
(1) GAT-3 ir astrocytic processes display a laminar segregation similar
to that of GAT-1 ir puncta (Minelli et al.;, 1995) and of GABAergic
axon terminals (Ribak, 1978 ; Houser et al., 1984 ); and (2)
GAT-3-positive astrocytic processes are not exclusively associated with
GABAergic profiles, as shown by double-labeling with GABA.
Axon terminals releasing GABA are densest in layer IV, followed by
layers II and III, and in layer Vb GABAergic terminals outline
unstained pyramidal cell bodies (Ribak, 1978 ; Freund et al., 1983 ;
Houser et al., 1984 ). These cortical layers or sublayers are also the
richest in GAT-1-positive puncta (Minelli et al., 1995 ). Here we have
shown that the distribution of GAT-3-positive puncta is similar to that
of axon terminals releasing GABA and of GAT-1-positive puncta. This
correlation implies that GAT-3 is highly expressed in the very
layers in which GABA is prominently released and, therefore,
highly concentrated. The presence of numerous ``patches'' devoid of
GAT-3 ir in neocortex indicates some differences in GAT-3 expression
and activity. The functional meaning of this organizational feature of
GAT-3 ir is at present unknown; it is worth noting, however, that an
analogous distribution has been reported for a glial glutamate (Glu)
transporter, GLT-1 (Rothstein et al., 1994 ).
GAT-3-positive puncta are in close relationship with neuronal
cell bodies and proximal dendrites, the major targets of GABAergic axon
terminals (Freund et al., 1983 ; Houser et al., 1984 ). To evaluate
directly the relationship between GAT-3-positive astrocytic processes
and GABA-releasing axon terminals, we combined preembedding ICC for
GAT-3 with postembedding immunogold labeling for the visualization of
GABA. The results of these experiments show that some GAT-3-stained
astrocytic processes are in direct contact with GABA-containing axon
terminals that are likely to release GABA. This observation suggests
that GAT-3 uptake mediates GABA reaccumulation in glial cells
surrounding GABAergic synapses, thus contributing to both termination
and regulation of GABAergic synaptic transmission (Isaacson et al.,
1993 ).
GAT-3-positive puncta, however, are also (1) scattered in the neuropil
and (2) close to axon terminals making asymmetric synapses. Their
functional role can be envisaged better bearing in mind that (1) GABA
may diffuse in the neuropil and therein act in a paracrine fashion and
(2) that this paracrine effect is potentiated by SKF-89976A, a
competitive blocker of GABA transport (Dingledine and Korn, 1985 ;
Thompson and Gahwiler, 1992 ; Isaacson et al., 1993 ). Because the
blocker used by Isaacson et al. (1993) is more potent at GAT-1 than at
GAT-3 (Borden et al., 1994b ), these findings suggest that the diffuse
action of GABA is modulated by GAT-1, but this does not rule out that
GAT-3 may also play a role. The availability of GAT-3-specific blockers
[e.g., (S)-SNAP-5114; Borden et al., 1994b ] will allow for
further evaluation of GAT-3's modulation of GABA's diffuse action.
Such a function of GAT-3 is strongly suggested by the presence of
numerous GAT-3-positive astrocytic processes in the neuropil. The
results presented here show that some GAT-3-positive astrocytic
processes are adjacent to axon terminals forming asymmetric synapses,
which contain and presumably release Glu (Conti and Minelli, 1996 ).
Interestingly, Isaacson et al. (1993) showed that inhibition of GABA
uptake enhances the presynaptic action of GABA on presumed
GABAB receptors located on excitatory nerve terminals.
GAT-3-positive astrocytic processes adjacent to axon terminals forming
asymmetric synapses could contribute, therefore, to the regulation of
GABA action on excitatory synaptic transmission.
Finally, it has been shown that GATs may release GABA in a
nonvesicular, Ca2+-independent manner (Schwartz, 1982 ;
Attwell et al., 1983; Levi and Raiteri, 1993). These data, together
with the present demonstration of a widespread distribution of
GAT-3-positive astrocytic processes in the neuropil, suggest that GAT-3
may mediate GABA release in the cerebral cortex.
FOOTNOTES
Received December 1, 1995; revised June 27, 1996; accepted July
8, 1996.
This work was supported by NATO (CRG 910273), Consiglio Nazionale delle
Ricerche (AI 90-01371, 91-00731, CT04), Ministero
dell'Università e della Ricerca Scientifica e Tecnologica,
National Institutes of Health (EY04067), VA Medical Research Funds and
Morphology Imaging CORE DK 41301. We thank Dr. Catia Sternini for
helpful comments and discussions, Ty K. Chen and Katherine Wen for
assistance in antibody production, purification, and characterization,
and Francesca Natalini for help with histology.
Correspondence should be addressed to Fiorenzo Conti, Istituto di
Fisiologia Umana, Università di Ancona, Via Ranieri, Monte
d'Ago, I-60131 Ancona, Italy.
REFERENCES
-
Attwell D,
Barbour B,
Szatkowski M
(1993)
Nonvesicular
release of neurotransmitter.
Neuron
11:401-407 .
[ISI][Medline]
-
Beaulieu C,
Campistron G,
Crevier C
(1994)
Quantitative
aspects of the GABA circuitry in the primary visual cortex of the adult
rat.
J Comp Neurol
339:559-572 .
[ISI][Medline]
-
Beart PM,
Johnston GAR,
Uhr ML
(1972)
Competitive inhibition
of GABA uptake in rat brain slices by some GABA analogues of restricted
conformation.
J Neurochem
19:1855-1861 .
[ISI][Medline]
-
Borden LA,
Smith KE,
Hartig PR,
Brancheck TA,
Weinshank RL
(1992)
Molecular heterogeneity of the
-aminobutyric
acid (GABA) transport system.
J Biol Chem
267:21098-21104 .
[Abstract/Free Full Text]
-
Borden LA,
Smith KE,
Vaysse PJ-J,
Weinshank RL,
Branchek TA
(1994a)
GABA transporters in neuronal and glial cell
cultures: correlation of pharmacological activity with mRNA
localization.
Soc Neurosci Abstr
20:919.
-
Borden LA,
Dhar TGM,
Smith KE,
Branchek TA,
Glucowski C,
Weinshank RL
(1994b)
Cloning of the human homologue of the GABA
transporter GAT-3 and identification of a novel inhibitor with
selectivity for this site.
Receptors Channels
2:207-213 .
[ISI][Medline]
-
Bowery NG,
Jones GP,
Neal MJ
(1976)
Selective inhibition of
neuronal GABA uptake by cis-1,3-aminocyclohexane carboxylic
acid (ACHC).
Nature
264:281-284.
[Medline]
-
Bradford MM
(1976)
A rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing the principle
of protein-dye binding.
Anal Biochem
72:248-254 .
[ISI][Medline]
-
Brecha NC,
Johnson J,
Chen T,
Conti F,
Minelli A,
DeBiasi S,
Ribak C
(1995)
GABA transporter expression in the rat nervous
system. Presynaptic mechanisms of neurotransmission.
Soc Neurosci Abstr
124:1.
-
Chapin JK,
Lin C-S
(1990)
The somatic sensory cortex of rat.
In: The cerebral cortex of the rat
(Kolb, B,
Tees, RG,
eds)
, p. 341. Cambridge: MIT.
-
Clark JA,
Amara SG
(1994)
Stable expression of a neuronal
-aminobutyric acid transporter, GAT-3, in mammalian cells
demonstrates unique pharmacological properties and ion dependence.
Mol Pharmacol
46:550-557 .
[Abstract]
-
Clark JA,
Deutch AY,
Gallipoli PZ,
Amara SG
(1992)
Functional
expression and CNS distribution of a
-alanine-sensitive neuronal
GABA transporter.
Neuron
9:337-348 .
[ISI][Medline]
-
Conti F,
Minelli A
(1996)
The anatomy of glutamatergic
transmission in the cerebral cortex.
In: Excitatory amino acids & the cerebral cortex
(Conti, F,
Hicks, TP,
eds)
, p. 81. Cambridge: MIT.
-
Corey JL,
Davidson N,
Lester HA,
Brecha NC,
Quick MW
(1994)
Protein kinase C modulates the activity of a cloned
-aminobutyric acid transporter expressed in Xenopus
oocytes via regulated subcellular redistribution of the transporter.
J Biol Chem
269:14759-14767 .
[Abstract/Free Full Text]
-
De Biasi S,
Vitellaro-Zuccarello L,
Bernardi P,
Valtschanoff JG,
Weinberg RJ
(1994)
Ultrastructural and immunocytochemical
characterization of primary afferent terminals in the rat cuneate
nucleus.
J Comp Neurol
347:275-287 .
[ISI][Medline]
-
Dingledine R,
Korn SJ
(1985)
-Aminobutyric acid uptake and
the termination of inhibitory synaptic potentials in the rat
hippocampal slices.
J Physiol (Lond)
366:387-409 .
[Abstract/Free Full Text]
-
During MJ,
Ryder KM,
Spencer DD
(1995)
Hippocampal GABA
transporter function in temporal lobe epilepsy.
Nature
376:174-177 .
[Medline]
-
Durkin MM,
Smith KE,
Borden LA,
Weinshank RL,
Branchek TA,
Gustafson EL
(1995)
Localization of messenger RNAs encoding three GABA
transporters in rat brain: an in situ hybridization study.
Mol Brain Res
33:7-21 .
[Medline]
-
Freund TF,
Martin KAC,
Smith AD,
Somogyi P
(1983)
Glutamate
decarboxylase-immunoreactive terminals of Golgi-impregnated axoaxonic
cells and presumed basket cells in synaptic contacts with pyramidal
neurons of the cat's visual cortex.
J Comp Neurol
221:263-278 .
[ISI][Medline]
-
Gavrilovic J,
Raff M,
Cohen G
(1984)
GABA uptake by purified
rat Swann cells in culture.
Brain Res
303:183-185 .
[ISI][Medline]
-
Gomeza J,
Casado M,
Gimenez C,
Aragon C
(1991)
Inhibition of
high-affinity
-aminobutyric acid uptake in primary astrocyte
cultures by phorbol esters and phospholipase C.
Biochem J
275:435-439 .
-
Guastella J,
Nelson N,
Nelson H,
Czyzyk L,
Keynan S,
Miedel MC,
Davidson N,
Lester HA,
Kanner BI
(1990)
Cloning and
expression of a rat brain GABA transporter.
Science
249:1303-1306 .
[Abstract/Free Full Text]
-
Guastella J,
Brecha NC,
Weigman C,
Lester HA,
Davidson N
(1992)
Cloning, expression, and localization of a rat brain
high-affinity glycine transporter.
Proc Natl Acad Sci USA
89:7189-7193 .
[Abstract/Free Full Text]
-
Houser CR, Vaughn GE, Hendry SHC, Jones EG, Peters
A (1984) GABA neurons in the cerebral cortex. In: Cerebral
cortex, Vol 2, Functional properties of cortical cells (Jones EG,
Peters A, eds), pp 63-90. New York: Plenum.
-
Hsu SM,
Raine L,
Fanger H
(1981)
Use of
avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques:
a comparison between ABC and unlabelled antibody (PAP) procedures.
J Histochem Cytochem
29:557-580.
-
Ikegaki N,
Saito N,
Hashima M,
Tanaka C
(1994)
Production of
specific antibodies against GABA transporter subtypes (GAT-1, GAT-2,
GAT-3) and their application to immunocytochemistry.
Mol Brain Res
26:47-54 .
[Medline]
-
Isaacson JS,
Solis JM,
Nicoll RA
(1993)
Local and diffuse
synaptic actions of GABA in the hippocampus.
Neuron
10:165-175 .
[ISI][Medline]
-
Iversen LL
(1971)
Role of transmitter uptake mechanisms in
synaptic neurotransmission.
Br J Pharmacol
41:571-591 .
[ISI][Medline]
-
Iversen LL,
Kelly JS
(1975)
Uptake and metabolism of
-aminobutyric acid by neurons and glial cells.
Biochemical Pharmacol
24:933-938 .
[ISI][Medline]
-
Iversen LL,
Neal MJ
(1968)
The uptake of
[3H]GABA by slices of rat cerebral cortex.
J Neurochem
15:1141-1149 .
[ISI][Medline]
-
Iversen LL,
Snyder SH
(1968)
Synaptosomes: different
population storing catecholamines and gamma-aminobutyric acid in
homogenate of rat brain.
Nature
220:796-798 .
[Medline]
-
Kanner BI,
Bendahan A
(1990)
Two pharmacologically distinct
sodium- and chloride-coupled high-affinity
-aminobutyric acid
transporters are present in plasma membrane vesicles and reconstituted
preparations from rat brain.
Proc Natl Acad Sci USA
87:2550-2554 .
[Abstract/Free Full Text]
-
Keynan S,
Suh Y-J,
Kanner BI,
Rudnick G
(1992)
Expression of
a cloned
-aminobutyric acid transporter in mammalian cells.
Biochemistry
31:1974-1979 .
[Medline]
-
Krogsgaard-Larsen P,
Falch E,
Larsson OM,
Schousboe A
(1987)
GABA uptake inhibitors: relevance to antiepileptic
drug research.
Epilepsy Res
1:77-93 .
[ISI][Medline]
-
Larsson OM,
Johnston GAR,
Schousboe A
(1983)
Differences in
uptake kinetics of cis-3-aminocyclohexane carboxylic acid
into neurons and astrocytes in primary cultures.
Brain Res
260:279-285 .
[ISI][Medline]
-
Levi G,
Raitieri M
(1993)
Carrier-mediated release of
neurotransmitters.
Trends Neurosci
16:415-418 .
[ISI][Medline]
-
Liu Q-R,
Lopez-Còrcuera B,
Mandiyan S,
Nelson H,
Nelson N
(1993)
Molecular characterization of four pharmacologically
distinct
-aminobutyric acid transporters in mouse brain.
J Biol Chem
268:2106-2112 .
[Abstract/Free Full Text]
-
Mabjeesh NJ,
Frese M,
Rauen T,
Jeserich G,
Kanner BI
(1992)
Neuronal and glial
-aminobutyric acid
transporters are distinct proteins.
FEBS Lett
299:99-102 .
[ISI][Medline]
-
Minelli A,
Brecha NC,
Karschin C,
DeBiasi S,
Conti F
(1995)
GAT-1, a high-affinity GABA plasma membrane
transporter, is localized to neurons and astroglia in the cerebral
cortex.
J Neurosci
15:7734-7746 .
[Abstract]
-
Neal MJ,
Bowery NG
(1977)
Cis-3-aminocyclohexane
carboxylic acid: a substrate for the neuronal GABA transport system.
Brain Res
138:169-174 .
[ISI][Medline]
-
Neal MJ,
Iversen LL
(1969)
Subcellular distribution of
endogenous and [3H]
-aminobutyric acid in rat cerebral
cortex.
J Neurochem
16:1245-1252 .
[ISI][Medline]
-
Peters A,
Palay SL,
Webster H deF H deF
(1991)
The
fine structure of the nervous system: neurons and their supporting cells.
.
-
Pin J-P,
Bockaert J
(1989)
Two distinct mechanisms,
differentially affected by excitatory amino acids, trigger GABA release
from fetal mouse striatal neurons in primary cultures.
J Neurosci
9:648-656 .
[Abstract]
-
Ribak CE
(1978)
Aspinous and sparsely-spinous stellate
neurons in the visual cortex of rat contain glutamic acid
decarboxylase.
J Neurocytol
7:461-478 .
[ISI][Medline]
-
Ribak CE,
Tong W,
Brecha NC
(1996)
The GABA plasma membrane
transporters, GAT-1 and GAT-3, display different distributions in the
rat hippocampus.
J Comp Neurol
367:595-606 .
[ISI][Medline]
-
Rothstein JD,
Martin L,
Levey AI,
Dykes-Hoberg M,
Jin L,
Wu D,
Nash M,
Kuncl RW
(1994)
Localization of neuronal and glial glutamate
transporters.
Neuron
13:713-725 .
[ISI][Medline]
-
Schon F,
Kelly JS
(1975)
Selective uptake of
[3H]
-alanine by glia: association with the glial
uptake system for GABA.
Brain Res
86:243-257 .
[ISI][Medline]
-
Schousboe A,
Larsson OM,
Wood JD,
Krogsgaard-Larsen P
(1983)
Transport and metabolism of
-aminobutyric acid in
neurons and glia: implications for epilepsy.
Epilepsia
24:531-538 .
[ISI][Medline]
-
Schwartz EA
(1982)
Calcium-independent release of GABA from
isolated horizontal cells of the toad retina.
J Physiol (Lond)
323:211-227 .
[Abstract/Free Full Text]
-
Thomas CT,
McNamee MG
(1990)
Purification of membrane
proteins.
Methods Enzymol
182:499-520.
[ISI][Medline]
-
Thompson SM,
Gahwiler BH
(1992)
Effects of the GABA uptake
inhibitor tiagabine on inhibitory synaptic potentials in rat
hippocampal slice cultures.
J Neurophysiol
67:1698-1670 .
[Abstract/Free Full Text]
-
Towbin H,
Staehelin T,
Gordon J
(1979)
Electrophoretic
transfer of proteins from polyacrylamide gels to nitrocellulose sheets:
procedure and some applications.
Proc Natl Acad Sci USA
76:4350-4354 .
[Abstract/Free Full Text]
-
Yamauchi A,
Uchida S,
Kwon HM,
Preston AS,
Robey RB,
Garcia-Perez A,
Burg MB,
Handler JS
(1992)
Cloning of a Na+- and
Cl
-dependent betaine transporter that is regulated by
hypertonicity.
J Biol Chem
267:649-652 .
[Abstract/Free Full Text]
-
Zilles K
(1985)
The cortex of rat.
.
This article has been cited by other articles:

|
 |

|
 |
 
S. Ellefsen, K.-O. Stenslokken, C. E. Fagernes, T. A. Kristensen, and G. E. Nilsson
Expression of genes involved in GABAergic neurotransmission in anoxic crucian carp brain (Carassius carassius)
Physiol Genomics,
January 1, 2009;
36(2):
61 - 68.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kirmse and S. Kirischuk
Ambient GABA constrains the strength of GABAergic synapses at Cajal-Retzius cells in the developing visual cortex.
J. Neurosci.,
April 19, 2006;
26(16):
4216 - 4227.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Casini, D. W. Rickman, and N. C. Brecha
Expression of the {gamma}-Aminobutyric Acid (GABA) Plasma Membrane Transporter-1 in Monkey and Human Retina.
Invest. Ophthalmol. Vis. Sci.,
April 1, 2006;
47(4):
1682 - 1690.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. A. Kinney
GAT-3 Transporters Regulate Inhibition in the Neocortex
J Neurophysiol,
December 1, 2005;
94(6):
4533 - 4537.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Keros and J. J. Hablitz
Subtype-Specific GABA Transporter Antagonists Synergistically Modulate Phasic and Tonic GABAA Conductances in Rat Neocortex
J Neurophysiol,
September 1, 2005;
94(3):
2073 - 2085.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Galvan, R. M. Villalba, S. M. West, N. T. Maidment, L. C. Ackerson, Y. Smith, and T. Wichmann
GABAergic Modulation of the Activity of Globus Pallidus Neurons in Primates: In Vivo Analysis of the Functions of GABA Receptors and GABA Transporters
J Neurophysiol,
August 1, 2005;
94(2):
990 - 1000.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Jiang, L. Zhuang, S. Miyauchi, K. Miyake, Y.-J. Fei, and V. Ganapathy
A Na+/Cl--coupled GABA Transporter, GAT-1, from Caenorhabditis elegans: STRUCTURAL AND FUNCTIONAL FEATURES, SPECIFIC EXPRESSION IN GABA-ERGIC NEURONS, AND INVOLVEMENT IN MUSCLE FUNCTION
J. Biol. Chem.,
January 21, 2005;
280(3):
2065 - 2077.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. A. Kinney and W. J. Spain
Synaptically Evoked GABA Transporter Currents in Neocortical Glia
J Neurophysiol,
December 1, 2002;
88(6):
2899 - 2908.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Barakat and A. Bordey
GAT-1 and Reversible GABA Transport in Bergmann Glia in Slices
J Neurophysiol,
September 1, 2002;
88(3):
1407 - 1419.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Cholet, L. Pellerin, P. J. Magistretti, and E. Hamel
Similar Perisynaptic Glial Localization for the Na+,K+-ATPase {alpha}2 Subunit and the Glutamate Transporters GLAST and GLT-1 in the Rat Somatosensory Cortex
Cereb Cortex,
May 1, 2002;
12(5):
515 - 525.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. L. Behar and D. L. Rothman
In Vivo Nuclear Magnetic Resonance Studies of Glutamate-{gamma}-Aminobutyric Acid-Glutamine Cycling in Rodent and Human Cortex: the Central Role of Glutamine
J. Nutr.,
September 1, 2001;
131(9):
2498S - 2504.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Masson, C. Sagne, M. Hamon, and S. E. Mestikawy
Neurotransmitter Transporters in the Central Nervous System
Pharmacol. Rev.,
September 1, 1999;
51(3):
439 - 464.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Conti, P. Barbaresi, M. Melone, and A. Ducati
Neuronal and Glial Localization of NR1 and NR2A/B Subunits of the NMDA Receptor in the Human Cerebral Cortex
Cereb Cortex,
March 1, 1999;
9(2):
110 - 120.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. PALACIN, R. ESTEVEZ, J. BERTRAN, and A. ZORZANO
Molecular Biology of Mammalian Plasma Membrane Amino Acid Transporters
Physiol Rev,
October 1, 1998;
78(4):
969 - 1054.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|